| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Pacific Biosciences (NASDAQ:PACB) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 0 | 1 | 3 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 1 | 0 | 0 |
| 3M Ago | 0 | 1 | 1 | 0 | 0 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $1.51, a high estimate of $1.80, and a low estimate of $1.25. A 14.2% drop is evident in the current average compared to the previous average price target of $1.76.
An in-depth analysis of recent analyst actions unveils how financial experts perceive Pacific Biosciences. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| David Westenberg | Piper Sandler | Raises | Neutral | $1.50 | $1.25 |
| Luke Sergott | Barclays | Lowers | Equal-Weight | $1.50 | $2.00 |
| David Westenberg | Piper Sandler | Lowers | Neutral | $1.25 | $2.00 |
| Mason Carrico | Stephens & Co. | Maintains | Overweight | $1.80 | $1.80 |
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Pacific Biosciences's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on Pacific Biosciences analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Pacific Biosciences's revenue growth over a period of 3M has faced challenges. As of 31 March, 2025, the company experienced a revenue decline of approximately -4.27%. This indicates a decrease in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Pacific Biosciences's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -1146.81%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Pacific Biosciences's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -142.44%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Pacific Biosciences's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -40.17%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Pacific Biosciences's debt-to-equity ratio is notably higher than the industry average. With a ratio of 7.63, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: PACB
